Aktieanalys

Active Biotech: Orphan Drug Designation for Tasquinimod in Myelofibrosis in the US - Redeye

{newsItem.title}

Redeye Publicerad: 19 May 2022 11:14

Redeye has a positive view of Active Biotech’s obtaining orphan drug status. We discuss the benefits in our comment.

Länk till analysen i sin helhet: https://www.redeye.se/research/842532/active-biotech-orphan-drug-designation-for-tasquinimod-in-myelofibrosis-in-the-us?utm_source=finwire&utm_medium=RSS

Nyheter om Active Biotech

Läses av andra just nu

Om aktien Active Biotech

Senaste nytt